Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
47 studies found for:    defend
Show Display Options
Rank Status Study
1 Completed Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: otelixizumab infusion plus physician determined standard of care;   Biological: placebo infusion plus physician determined standard of care
2 Completed Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: Otelixizumab;   Biological: Placebo
3 Not yet recruiting Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older
Condition: Nocturia
Interventions: Drug: Desmopressin;   Drug: Fesoterodine
4 Completed Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
Condition: Endometrial Cancer
Intervention: Drug: Letrozole
5 Recruiting Exercise and Weight Control
Conditions: Overweight;   Obese
Interventions: Other: Exercise Energy Expenditure 300 kcal/day;   Other: Exercise Energy Expenditure 600 kcal/day
6 Terminated Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure
Condition: Acute Decompensated Heart Failure; Renal Dysfunction
Interventions: Drug: SLV320;   Drug: Placebo
7 Completed Metabolic Adaptation to Diabetes
Condition: Type 2 Diabetes
Intervention: Procedure: glucose clamp
8 Completed Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2
Condition: Type 1 Diabetes
Interventions: Drug: Alprazolam;   Other: control group
9 Active, not recruiting Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine
Condition: Type 1 Diabetes
Interventions: Drug: Atomoxetine;   Drug: Placebo
10 Active, not recruiting Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2
Condition: Type 1 Diabetes
Interventions: Drug: Alprazolam;   Drug: Placebo
11 Not yet recruiting Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Myeloproliferative Syndromes;   Plasma Cell Myeloma;   Colon Carcinoma;   Adenocarcinoma of Rectum;   Soft Tissue Sarcoma;   Ewing's Sarcoma;   Rhabdomyosarcoma
Interventions: Biological: Natural Killer (NK) Cells;   Biological: ALT803
12 Recruiting Investigation of Immune Disorders and Deficiencies
Conditions: Primary Immune Deficiencies;   Autoimmune Diseases;   Inflammatory Diseases;   Common Variable Immune Deficiencies;   Hypogammaglobulinemia
Intervention:
13 Completed Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
Condition: Endometrial Carcinoma
Intervention: Drug: carboplatin, paclitaxel, and bevacizumab
14 Recruiting Detection and Characterization of Infections and Infection Susceptibility
Conditions: Immune Disorders;   Chronic Granulomatous Disease;   Genetic Immunological Deficiencies;   Hyperimmunoglobulin-E Recurrent Infection Syndrome;   Recurrent Infections;   Unknown Immune Deficiency;   GATA2 Deficiency (MonoMAC),;   Nontuberculous Mycobacterial Infections;   Hyper IgE (Job s) Syndrome;   Leukocyte Adhesion Deficiency;   Susceptibility to Disseminated Infections;   Primary Immune Deficiency Disease (PIDD)
Intervention:
15 Completed Peer Interactions and Food Are Substitutable in Youth
Conditions: Activity Choices;   Caloric Intake;   Social Time
Intervention:
16 Unknown  Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Conditions: Scleroderma;   Interstitial Lung Disease
Interventions: Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Placebo
17 Completed Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children
Condition: HIV Infections
Intervention: Drug: CD4-IgG2
18 Active, not recruiting The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease
Conditions: Chronic Obstructive Pulmonary Disease (COPD);   Smoking;   Smoking Cessation;   Chronic Bronchitis;   Emphysema
Intervention:
19 Completed Glutamine Supplementation in Cystic Fibrosis
Conditions: Cystic Fibrosis;   Immune Function
Interventions: Dietary Supplement: Glutamine;   Dietary Supplement: L-alanine
20 Enrolling by invitation KiVa Anti-bullying Program in Chile: Evaluation of Effectiveness With and Without the Digital Game Component
Condition: Bullying
Intervention: Other: KiVa program

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years